Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase

Disclosed are compounds of the Formula I 1 wherein: R a , R b , and R c are the same or different and represent hydrogen, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl; R 1 and R 2 are the same or different and represent hydrogen, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl; n is 0, 2, or 3, provided that when the imidazole is attached at the imidazole nitrogen to (CR a R b ) n and Y is O, NR c , or S, then n is not 0; Y is NR c , O, -CHR c , or S; and R 3 is unsubstituted aryl, unsubstituted heteroarylalkyl or unsubstituted arylalkyl. The present invention also provides a pharmaceutically acceptable composition that comprises a compound of Formula I. The present invention also provides a method of treating or preventing restenosis, atherosclerosis or cancer, the method comprising administering to a patient having restenosis, atherosclerosis or cancer, or at risk of having restenosis, atherosclerosis or cancer, a therapeutically effective amount of Formula I. Also provided is a method of treating or preventing restenosis or atherosclerosis, or treating cancer, the method of comprising administering to a patient having restenosis or atherosclerosis, or at risk of having restenosis or atherosclerosis, or having cancer a therapeutically effective amount of a compound of Formula I.